primary sclerosing cholangitis

View All

Pharma News for AskBio, Almirall, Bayer, Pfizer
Key Updates on Phase 1 Trial of AB-1005 Gene Therapy for Multiple System Atrophy-Parkinsonian Type; European Commission Approves EBGLYSS; Bayer Stopped OCEANIC-AF Study; Pfizer and Astellas’ XTANDI Approved by FDA; FDA Orphan Drug Designation to Epic Bio’s EPI-321; FDA Fast Track Designation to Chemomab’s CM-101 for PSC

AskBio Announces First Patient Randomized in Phase 1 Trial of AB-1005 Gene Therapy for Multiple System Atrophy-Parkinsonian Type Asklepios BioPharmaceutical, Inc., a gene therapy firm fully owned and independently operated under Bayer AG, announced the initiation of the Phase I REGENERATE MSA-101 clinical trial ...

Find More

primary-sclerosing-cholangitis-treatment-landscape
Novel Insights of Primary Sclerosing Cholangitis Treatment Market

There are a few major unmet needs in the primary sclerosing cholangitis (PSC) treatment market, which include a lack of effective therapies, proven surveillance strategies, tools for early detection of malignancies, impact on quality of life (QoL), and surrogate endpoints in primary sclerosing cholangitis clinical ...

Find More

cholangiocarcinoma
What is Cholangiocarcinoma (CCA)?

Cholangiocarcinoma (BILE Duct cancer) is a type of uncommon CANCER. It arises in Bile ducts. The Bile duct is a long tubule like structure which connects the liver (hepatic duct) to the gall bladder (cystic duct). It carries bile, which helps in digestion of food, from gall-bladder (produced in the liver) to inte...

Find More